ViThera develops new drugs based on engineered beneficial bacteria
ViThera develops new drugs based on engineered beneficial bacteria. Our lead product VT201 targets IBD, such as Crohn's or Colitis, a significant unmet need, and addresses a $10bn/yr market. VT201 is a food strain bacterium (Lactococcus Lactis, typical component of cheese) engineered to express an anti-inflammatory protein which controls inflammation in the gut-after oral intake of the therapeutic bacteria. We have a uniquely experienced team and strong exclusive IP position.